Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal

Ropivacaine

Summary

The data on hazard and risk are based on previous environmental information on fass.se. Environmental information is missing on fass.se (2021-10-27). It is voluntary for manufacturers to provide information about environmental impact on fass.se.

Persistence. Ropivacaine is potentially persistent.
Bioaccumulation. Ropivacaine has no significant bioaccumulation potential.
Toxicity. Ropivacaine has moderate acute toxicity.
Risk. The use of ropivacaine (sales data Sweden 2009) has been considered to result in insignificant environmental risk.

Detailed information

Fass environmental information

Fass environmental information for Narop (ropivacaine) from AstraZeneca (downloaded 2011-05-27).

Hazard

Persistence: "The aerobic biodegradability was determined in accordance with ISO 7827-1984 (E) (Ref. 1), using the OECD guidelines’ criteria for ready biodegradation. According to the results, ropivacaine is not readily biodegradable (loss of Dissolved Organic Carbon (DOC) < 70% after 28 days)."

Bioaccumulation: Log D = 2.06 at pH 7.4 (25ºC) (experimental).

Acute toxicity: There are data for 3 trophic levels, most sensitive crustacean (Daphnia magna) EC50 (Immobilisation) 48 h = 34 mg/L.

Risk

PEC/PNEC is based on sales data in Sweden in year 2009. PEC/PNEC = 1,4 x 10-4 which gives the risk insignificant.

Author: Health and Medical Care Administration, Region Stockholm